Wall Street analysts predict that Idexx Laboratories (NASDAQ:IDXX) will post earnings per share of $1.18 for the current quarter, Zacks reports. Five analysts have made estimates for Idexx Laboratories’ earnings. The highest EPS estimate is $1.21 and the lowest is $1.16. Idexx Laboratories reported earnings per share of $0.95 in the same quarter last year, which indicates a positive year-over-year growth rate of 24.2%. The company is expected to issue its next earnings report on Tuesday, August 7th.
According to Zacks, analysts expect that Idexx Laboratories will report full year earnings of $4.17 per share for the current financial year, with EPS estimates ranging from $4.14 to $4.21. For the next financial year, analysts forecast that the firm will post earnings of $4.90 per share, with EPS estimates ranging from $4.80 to $5.03. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Idexx Laboratories.
Idexx Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Friday, May 4th. The company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.09. The company had revenue of $537.60 million for the quarter, compared to analysts’ expectations of $525.14 million. Idexx Laboratories had a negative return on equity of 530.24% and a net margin of 13.87%. The business’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.77 earnings per share.
Several brokerages recently commented on IDXX. Stifel Nicolaus upped their target price on Idexx Laboratories from $215.00 to $225.00 and gave the company a “buy” rating in a report on Monday, May 7th. Canaccord Genuity reiterated a “positive” rating and issued a $215.00 target price on shares of Idexx Laboratories in a report on Monday, May 7th. BidaskClub cut Idexx Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 9th. Zacks Investment Research cut Idexx Laboratories from a “buy” rating to a “hold” rating in a report on Thursday. Finally, ValuEngine upgraded Idexx Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Idexx Laboratories presently has a consensus rating of “Buy” and a consensus target price of $202.00.
In related news, Director Daniel M. Junius sold 2,974 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $190.06, for a total value of $565,238.44. Following the sale, the director now directly owns 5,602 shares in the company, valued at $1,064,716.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William T. End sold 9,470 shares of the company’s stock in a transaction that occurred on Thursday, May 10th. The shares were sold at an average price of $208.36, for a total value of $1,973,169.20. Following the completion of the sale, the director now owns 31,786 shares in the company, valued at $6,622,930.96. The disclosure for this sale can be found here. Corporate insiders own 2.56% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Cabot Wealth Management Inc. lifted its stake in Idexx Laboratories by 3.5% in the fourth quarter. Cabot Wealth Management Inc. now owns 9,050 shares of the company’s stock valued at $1,415,000 after buying an additional 309 shares during the period. Daiwa Securities Group Inc. lifted its stake in Idexx Laboratories by 13.3% in the first quarter. Daiwa Securities Group Inc. now owns 2,945 shares of the company’s stock valued at $564,000 after buying an additional 346 shares during the period. Catalyst Capital Advisors LLC lifted its stake in Idexx Laboratories by 2.3% in the fourth quarter. Catalyst Capital Advisors LLC now owns 17,600 shares of the company’s stock valued at $2,752,000 after buying an additional 400 shares during the period. Front Row Advisors LLC lifted its stake in Idexx Laboratories by 9.8% in the first quarter. Front Row Advisors LLC now owns 4,556 shares of the company’s stock valued at $872,000 after buying an additional 405 shares during the period. Finally, Schaper Benz & Wise Investment Counsel Inc. WI lifted its stake in Idexx Laboratories by 0.8% in the fourth quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 57,470 shares of the company’s stock valued at $8,987,000 after buying an additional 430 shares during the period. 86.14% of the stock is currently owned by hedge funds and other institutional investors.
IDXX stock traded up $1.33 during trading on Friday, hitting $203.70. The company had a trading volume of 360,200 shares, compared to its average volume of 532,669. Idexx Laboratories has a one year low of $146.09 and a one year high of $217.89. The stock has a market capitalization of $17.73 billion, a PE ratio of 62.10, a PEG ratio of 2.43 and a beta of 0.60. The company has a debt-to-equity ratio of -12.43, a current ratio of 0.96 and a quick ratio of 0.72.
About Idexx Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Idexx Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.